MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after ...

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws.On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the full year of 2025." In the same remarks, CEO Robert Ragusa stated: "We believe our cash ...

Grail (NASDAQ: GRAL) stock rose by more than 16% by midday. The move follows a couple of days of brutal declines after the release of top-line results from its three-year, 142,000-person trial of its Galleri multi-cancer early detection (MCED) test with England's National Health Service. What went wrong for Grail I discussed the stock's decline on the first day of trading after the release, and the market punished it again on Monday. However, let's focus on why the market may be optimistic about future dev ...

GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- The law firm of [Robbins Geller Rudman & Dowd LLP] is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL).If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who su ...

Shares of cancer-detection firm Grail (NASDAQ: GRAL) fell by half in last Friday's trading session. That's quite a turnabout after the company's share price more than quintupled in 2025, from about $19 a share in January to $110 in November. Last week shares of the California-based biotech were trading at around $102. Today they're priced at $49. What happened? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" ...

Grail (NASDAQ: GRAL) stock came under even more pressure today, declining by more than 16% by 12:40 a.m. The move comes as the market continues to digest the unpalatable news that hit the market on Friday. The news wasn't good, but there is a pathway to recovery, however tenuous it might appear now. What happened to Grail stock recently I discussed the game-changing event on Friday. Simply put, the company's trial of its Galleri multi-cancer early detection (MCED) with England's National Health Service (N ...

On February 17, 2026, Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL (NASDAQ:GRAL), an estimated $39.33 million trade based on quarterly average pricing. What happened According to a recent SEC filing dated February 17, 2026, Baker Bros. Advisors increased its position in GRAIL by 455,208 shares. The estimated transaction value, based on the average unadjusted closing price during the fourth quarter of 2025, was $39.33 million. The quarter-end value of the position rose by $82.09 mi ...

GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.NHS-Galleri Trial ResultsThe NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.The trial evaluated annual multi-cancer screening with the Galleri test i ...

Group 1 - A T206 Honus Wagner baseball card was sold at auction for $5.124 million, making it the third-most expensive T206 Wagner card ever sold [1] - The auction was conducted by Goldin Auctions and included the buyer's premium [1] - Previous sales of T206 Wagner cards reached $6.606 million in August 2021 and $7.25 million in August 2022 [1] Group 2 - The recently discovered card had been in the Shields family for 116 years, originally collected by their grandfather, Morton Bernstein [2] - Morton Bernstein was the son of the founder of The National Silver Company and preserved trading cards since the early 1900s [2] - The card was graded as a 1 by Professional Sports Authenticator (PSA), while the other two Wagner cards received grades of 3 and 2 from Sportscard Guaranty Corporation (SGC) [5] Group 3 - The T206 Wagner card was featured on Netflix's "King of Collectibles: The Goldin Touch" in December [7] - Scarcity is a significant factor in the value of collectibles, as Wagner requested the American Tobacco Company to stop producing his card in 1909 [9] - Wagner is a highly recognized baseball player, known for winning the World Series with the Pittsburgh Pirates and being one of the original Hall of Fame inductees [11]

Core Viewpoint - Grail's stock experienced a significant decline, losing more than half its value following a failed trial of its Galleri early-detection cancer test, which did not meet its primary endpoint [1] Group 1: Company Performance - Grail's shares were the biggest losers on the Nasdaq, reflecting investor disappointment after the trial results [1] - The stock price had nearly doubled over the past year due to high expectations for strong trial results [1] Group 2: Industry Impact - Illumina, a major shareholder in Grail, also saw its stock take a hit as a result of the failed trial [1]